Navigation Links
VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009
Date:11/4/2009

rty related to our product candidates;
  • our potential for future growth and the development of our product pipeline, including the THR beta agonist candidate and the other compounds licensed from Roche;
  • our ability to obtain strategic opportunities to partner and collaborate with large biotechnology or pharmaceutical companies to further develop VIA-2291;
  • our ability to form and maintain collaborative relationships to develop and commercialize our product candidates;
  • general economic and business conditions; and
  • the other risks described under Item 1A "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2008, as supplemented by the risks described under Item 1A "Risk Factors" in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2009 and June 30, 2009, each on file with the SEC.
  • All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of the date they are made, and VIA undertakes no obligation to update publicly any of these statements in light of new information or future events.

    SOURCE VIA Pharmaceuticals, Inc.


    '/>"/>
    SOURCE VIA Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Reportlinker Adds Gastrointestinal Pharmaceuticals: Technologies and Markets
    2. Peregrine Pharmaceuticals Regains Full Compliance With Nasdaq Continued Listing Requirements
    3. Isis Pharmaceuticals to Present at the 2009 Canaccord Adams Cardiovascular Conference
    4. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
    5. Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
    6. Warner Chilcott Completes Acquisition of P&Gs Global Branded Prescription Pharmaceuticals Business
    7. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
    8. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
    9. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
    10. Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full-Year Financial Guidance
    11. Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Ranibizumab Market, 2012-2019" ... ranibizumab was approved by CFDA to treat wet age- ... a product of Novartis, is available in the Chinese ... developed drug for the treatment of wet AMD in ...
    (Date:8/28/2015)... Aug. 28, 2015 Perrigo Company plc ("Perrigo") ... Mylan N.V. ("Mylan") (NASDAQ: MYL ) shareholder vote ... "Our views of Mylan,s offer to Perrigo shareholders ... on our Board,s careful reflection of the value available ... limited choices that Mylan has allowed its shareholders to ...
    (Date:8/28/2015)... HERTFORDSHIRE, England and PITTSBURGH ... (NASDAQ: MYL ) today announced that its ... Company plc (NYSE: PRGO ; TASE) and ... Perrigo,s shareholders at an extraordinary general meeting of ... of two-thirds of the votes cast at the extraordinary general ...
    Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9
    ... ADDISON, Texas and SALT LAKE CITY, Feb. 28, 2011 ... HUM ), is transforming the future of occupational ... improvements, creating exceptional and engaging experiences for clients and ... Concentra has joined the ranks of top U.S. consumer ...
    ... 28, 2011 ViroPharma Incorporated (Nasdaq: VPHM ) ... of ViroPharma, will present at the Citi 2011 Global Healthcare ...  The conference is being held at the Hilton New York ... president and chief financial officer, of ViroPharma, will present at ...
    Cached Medicine Technology:Concentra is Writing a New Prescription on Health Care With Outstanding Service 2Concentra is Writing a New Prescription on Health Care With Outstanding Service 3Concentra is Writing a New Prescription on Health Care With Outstanding Service 4Concentra is Writing a New Prescription on Health Care With Outstanding Service 5ViroPharma to Participate in Two March Healthcare Conferences 2
    (Date:8/30/2015)... ... August 30, 2015 , ... InHealth Media ( http://www.inhealthmedia.com ... Global Communications Director for InHealth Media. Mr. Spector comes with a wide ... years doing on-air television, producing shows, on air-radio and media relations. , ...
    (Date:8/30/2015)... ... August 30, 2015 , ... ... medical devices for the treatment of prostate cancer, has announced the roll-out of ... at the treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology currently ...
    (Date:8/29/2015)... ... August 29, 2015 , ... "I have ... Miller Place, N.Y. "I specialize in manual therapy, and my invention will provide ... be used for additional muscle dysfunction throughout the body." , They developed THE ...
    (Date:8/29/2015)... ... 2015 , ... Next weekend is Labor Day weekend, the last bash of ... 22nd this year). For IT security personnel, it should also mark the perfect time ... more costly than a simple headache. , Joe Caruso, founder and CEO-CTO of ...
    (Date:8/29/2015)... ... 29, 2015 , ... Vascular Health Sciences announced today that ... Arterosil HP, and that all claims and counterclaims have been irrevocably dismissed. , ... in the United States District Court for the Southern District of Texas for ...
    Breaking Medicine News(10 mins):Health News:InHealth Media Appoints New Global Communications Director 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4
    ... ,Genzyme Corporation (Nasdaq: GENZ ) and Bioenvision, ... Bioenvision stockholders have voted to,approve the acquisition of ... meeting in New York. The transaction will be ... the company will,be delisted from Nasdaq. Fifty-six ...
    ... Vanda Pharmaceuticals,Inc. (Nasdaq: VNDA ) announced today ... of iloperidone at the 57th American Society of ... San Diego, CA, from October 23,through October 27, ... filing for iloperidone on September 27, 2007. Iloperidone ...
    ... evacuees to register on Safe and Well Website, ... California, forcing thousands to evacuate the area. During this,ongoing ... may feel confused,and anxious about the safety of their ... all those who have evacuated or who expect to,evacuate ...
    ... A team of Johns Hopkins scientists reports in this weeks ... that humans can be protected against the damaging effects of ... our environment by topical application of an extract of ... by parallel evidence obtained in mice, show that the degree ...
    ... 22 Shire plc (LSE: SHP,Nasdaq: SHPGY, TSX: ... (ADHD), announced today that it will present key,scientific ... scientific and,educational meeting of child and adolescent psychiatrists ... Shire studies to be presented are indicative of ...
    ... 22 HealthShares(TM) Inc., an investment,company with a series ... informed by Standard & Poor,s, the calculating agent for ... on,Thursday October 25, 2007, Amag Pharmaceuticals (Nasdaq: AMAG ... the HealthShares(TM) Diagnostics Index, and,Hologic Inc. (Nasdaq: HOLX ...
    Cached Medicine News:Health News:Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 2Health News:Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 3Health News:Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 4Health News:Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting 2Health News:Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting 3Health News:Southern California Wildfires Continue to Threaten Residential Areas 2Health News:Southern California Wildfires Continue to Threaten Residential Areas 3Health News:Broccoli sprout-derived extract protects against ultraviolet radiation 2Health News:Shire to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting 2Health News:Shire to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting 3Health News:Shire to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting 4Health News:Shire to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting 5Health News:HealthShares(TM) Announces Changes to the HealthShares(TM) Diagnostics and Composite Indexes 2Health News:HealthShares(TM) Announces Changes to the HealthShares(TM) Diagnostics and Composite Indexes 3
    The Doro Halo retractor system is designed for all neurosurgical applications where retraction of the brain tissue and an armrest is required....
    Molt 9, excellent for subperiosteal tunneling....
    Love-Adson periosteal elevator, semi sharp, blade width 3/16" (5 mm), length 6 1/2" (165 mm)....
    Iowa University periosteal elevator, blade width 11/16" (17 mm), length 7 1/4" (184 mm)....
    Medicine Products: